Cite
Pataky RE, Beca J, Tran D, et al. Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. MDM Policy Pract. 2021;6(1):23814683211021060doi: 10.1177/23814683211021060.
Pataky, R. E., Beca, J., Tran, D., Dai, W. F., Dvorani, E., Isaranuwatchai, W., Peacock, S., Alvi, R., Cheung, W. Y., Earle, C. C., Gavura, S., & Chan, K. K. W. (2021). Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. MDM policy & practice, 6(1), 23814683211021060. https://doi.org/10.1177/23814683211021060
Pataky, Reka E, et al. "Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces." MDM policy & practice vol. 6,1 (2021): 23814683211021060. doi: https://doi.org/10.1177/23814683211021060
Pataky RE, Beca J, Tran D, Dai WF, Dvorani E, Isaranuwatchai W, Peacock S, Alvi R, Cheung WY, Earle CC, Gavura S, Chan KKW. Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. MDM Policy Pract. 2021 Jun 19;6(1):23814683211021060. doi: 10.1177/23814683211021060. eCollection 2021. PMID: 34212111; PMCID: PMC8216386.
Copy
Download .nbib